1. Pancreatitis: Definitions
Pancreatitis is characterized by inflammation of the pancreas. In some individuals it may progress from acute (sudden onset; duration <6 months) to recurrent acute (>1 episode of acute pancreatitis) to chronic (duration >6 months). The range of symptoms and disease course vary from person to person.
Hereditary pancreatitis. The term hereditary pancreatitis is generally reserved for individuals and families with germline highly penetrant heterozygous gain-of-function variants in PRSS1 (e.g., p.Asn29Ile, p.Arg122His).
Familial pancreatitis. Familial pancreatitis is used to describe kindreds with two or more closely related individuals (up to second-degree relatives) with pancreatitis. Other causes of pancreatitis must be excluded, including PRSS1-related hereditary pancreatitis, CFTR-related pancreatitis, gallstones, trauma, and other common etiologies.
Acute pancreatitis (AP) is diagnosed in the presence of two of the following three findings [Banks et al 2006]:
Manifestations of AP can range from vague abdominal pain lasting one to three days to severe abdominal pain, systemic inflammation, and multiorgan failure lasting days to weeks and requiring hospitalization with care in an intensive care unit (i.e., severe acute pancreatitis [SAP]).
Recurrent acute pancreatitis (RAP) is a condition defined by more than one episode of AP [Guda et al 2018]. In children, it is often called acute recurrent pancreatitis (ARP) to distinguish it from recurrent abdominal pain (often abbreviated as RAP).
Chronic pancreatitis (CP) has been redefined as a "pathologic fibro-inflammatory syndrome of the pancreas in individuals with genetic, environmental, and/or other risk factors who develop persistent pathologic responses to parenchymal injury or stress" [Whitcomb 2019]. The definition promotes the identification of disorders that may lead to CP before an irreversible stage is reached, and to guide targeted treatment of the cause rather than the symptoms. Clinical features of CP include pancreatic atrophy, fibrosis, pain, duct distortion and strictures, calcifications, pancreatic exocrine dysfunction, pancreatic endocrine dysfunction, and dysplasia.
Early CP. Individuals at risk for CP are initially asymptomatic with no disease features or symptoms. An event occurs (e.g., passing a gallstone), that initiates an AP attack. The immune system in the pancreas is activated, making the pancreas hypersensitive to future injury. This is typically followed by complete healing. However, some scarring may occur with continued inflammation, resulting in early CP. Early CP is poorly defined because the inflammation and fibrosis may be reversible, and the early imaging changes are nonspecific. While early CP cannot be accurately diagnosed as CP [Whitcomb et al 2018], it is possible to diagnose one of several underlying disorders that can be treated to prevent further progression.
Established CP represents progression to irreversible pancreatic damage, typically based on scarring or fibrosis identified with imaging studies. The clinical presentation can vary among affected individuals.
End-stage CP occurs when the function of the remaining cells (both exocrine and endocrine) falls below the physiologic needs of the affected individual, requiring both pancreatic enzyme replacement therapy and insulin.
In most populations, about one third of individuals with AP develop RAP, and about one third of individuals with RAP develop CP. Because of the high risk of progression to an irreversible condition, efforts to stop the progression should begin with the first episode of AP.
Clinical Features of CP
The pancreas has two cell types in the exocrine pancreas: acinar cells that secrete zymogens (inactive digestive enzymes), and duct cells that flush the zymogens into the small intestine where they become active. The endocrine pancreas has four cell types, collectively referred to as islet cells. Beta cells are the most important as they secrete insulin. Alpha cells secrete glucagon, an antagonist of insulin. The last two islet cell types secrete pancreatic polypeptide and somatostatin. In addition, the pancreas has a rich nerve innervation including sensory nerves. The inflammatory process can destroy any of the parenchymal cells, activate nerves causing pain, and cause DNA damage to acinar and duct cells, thereby increasing the risk for pancreatic ductal adenocarcinoma. Damage to islet cells may increase the risk for neuroendocrine tumors.
Exocrine pancreatic insufficiency (EPI) is the reduction in pancreatic enzyme quantity and/or activity to a level below the threshold required to maintain normal digestion. In CP, EPI occurs when the acinar cells cannot make sufficient zymogens and deliver them to the intestinal tract to digest food so that it can be absorbed and meet nutritional needs. Clinical signs include steatorrhea (fat and oil in the stool), symptoms of maldigestion (bloating, gas, cramps, and diarrhea), and nutritional deficiencies (e.g., fat-soluble vitamin deficiency including A, D, E and K, vitamin B12, and protein malnutrition with low albumin, prealbumin, or retinal binding protein). Individuals with EPI require pancreatic enzyme replacement therapy.
Pancreatic endocrine insufficiency. With advanced CP, with or without surgical resection, insulin-producing beta cells are destroyed, resulting in insulin deficiency and pancreatogenic diabetes mellitus (type3c DM) [Andersen et al 2013]. In type3c DM, there is a reduction in insulin, glucagon, and pancreatic polypeptide. In earlier stages of CP, DM may develop as a result of selective dysfunction of the beta cells from autoantibodies (type 1 DM), beta-cell dysfunction from other genetic risk factors, peripheral insulin resistance similar to type 2 DM, or other rare types of diabetes. DM develops in about a third of individuals with CP, and most of these individuals have environmental/metabolic and/or genetic risks for type 2 DM [Bellin et al 2017, Goodarzi et al 2019].
Pain, the primary symptom in persons with CP, originates in the abdomen in response to pancreatic injury. Pain character, frequency, and severity are highly variable. As the disease progresses, pain may convert to constant neuropathic pain, which cannot be controlled even by major interventions such as spinal block or total pancreatectomy.
Pancreatic cancer risk is increased after age 50 years in those with longstanding chronic inflammation of the pancreas. Persons with hereditary pancreatitis are at high risk because their age at onset of CP is 20-30 years earlier than in sporadic forms of CP. Although an earlier study estimated lifetime risk for pancreatic cancer at 40%, this estimate was suspected to have been obtained in populations with high rates of smoking, a risk factor that doubles the risk for pancreatic cancer in individuals with hereditary pancreatitis [Lowenfels et al 2001]. For nonsmokers the lifetime risk may be below 20% [Rebours et al 2008, Rebours et al 2009, Shelton et al 2018].
3. Evaluation Strategies to Identify Genetic Risk Factors in a Proband with Pancreatitis
The evaluation of an individual at risk for chronic pancreatitis (CP) should begin at the time of the first episode of acute pancreatitis (AP), after common causes of AP have been ruled out such as a gallstone, trauma, hypertriglyceridemia, or hypercalcemia. If another etiology for AP is not identified, molecular genetic testing is indicated [Kleeff et al 2017, Guda et al 2018, Vivian et al 2019].
Establishing a specific genetic cause of pancreatitis:
Can aid in discussions of prognosis (which are beyond the scope of this
GeneReview) and
genetic counseling;
Usually involves a medical and family history, physical examination, and
genomic/genetic testing.
Medical and Family History
The most important part of the clinical evaluation is a careful family history and review of systems. The objective is to identify familial disorders such as hereditary pancreatitis, CFTR-related disorders, Shwachman-Diamond syndrome, or familial hypertriglyceridemia (see Table 2). Diabetes mellitus and pancreatic cancer may be surrogates for undiagnosed CP in older generations. The review of symptoms should focus on features of cystic fibrosis (e.g., sinorespiratory infections, nasal polyps, sinusitis, bronchiectasis, bronchitis, pneumonia, constipation, male infertility, pancreatitis symptoms) and Shwachman-Diamond syndrome (e.g., pancreatic insufficiency, short stature, maldigestion, neutropenia, frequent middle-ear and other infections, progressive marrow failure, myelodysplastic syndrome). The medical history may be able to exclude alternate etiologies of pancreatitis, such as biliary pancreatitis, hyperlipidemia, autoimmune disorders, obstructive pancreatitis, medications, or infections.
Early-onset pancreatitis (age <35 years) is often indicative of pancreatitis with an underlying genetic etiology (e.g., single-gene or polygenic disorder), whereas late-onset pancreatitis may indicate a complex pathology with both genetic and environmental causes.
Ongoing and high levels of alcohol and tobacco use may indicate an alcohol-related etiology, but excessive alcohol use does not exclude consideration of genetic risk for pancreatitis.
Molecular genetic testing for hereditary pancreatitis is indicated in a proband with pancreatitis and at least one of the following:
An unexplained documented episode of acute pancreatitis in childhood
Recurrent acute attacks of pancreatitis of unknown cause
Chronic pancreatitis of unknown cause, particularly with onset before age 35 years without a history of heavy alcohol use (>5 drinks per day).
A history of at least one relative with recurrent acute pancreatitis, chronic pancreatitis of unknown cause, or childhood pancreatitis of unknown cause
Physical Examination
The physical examination should focus on identifying syndromes associated with pancreatitis (see Table 2) since the pancreas cannot be directly evaluated on physical examination. These include assessment of growth and for signs of cystic fibrosis (nasal polyps, pulmonary examination).
Molecular Genetic Testing
Molecular genetic testing approaches can include a combination of gene-targeted testing (single-gene testing or multigene panel) and comprehensive genomic testing (exome sequencing, genome sequencing). Gene-targeted testing requires the clinician to hypothesize which gene(s) are likely involved, whereas genomic testing does not.
Serial single-gene testing can be considered if clinical findings and/or family history indicates that pathogenic variants in a particular gene are most likely (see
Table 1). Sequence analysis detects small intragenic deletions/insertions and
missense,
nonsense, and
splice site variants; typically,
exon or whole-gene deletions/duplications are not detected. Perform
sequence analysis of
PRSS1 first. If no
pathogenic variant is found, perform gene-targeted
deletion/duplication analysis to detect intragenic deletions or duplications.
Note: (1)
PRSS1 has very high homology with other trypsinogen genes and pseudogenes, and the pathogenic variants often result from
gene conversion events between trypsinogen genes or pseudogenes. Regardless of the sequencing method employed, primers must be carefully chosen and validated to amplify the fragment for the correct gene and transcript. Thus, a multistep method may be required to verify the presence of a
pathogenic variant in
PRSS1. (2) If a
proband is reported to have a
PRSS1 pathogenic variant and the parents are negative for this pathogenic variant, the possibility of a false positive result in the proband can be evaluated by reviewing the test methodology (
exome and
genome sequencing may result in a false positive
PRSS1 result) and possibly retesting the proband.
A multigene panel that includes some or all of the genes listed in the
Table 1 is most likely to identify the genetic cause of the condition while limiting identification of variants of
uncertain significance and pathogenic variants in genes that do not explain the underlying
phenotype. Note: (1) The genes included in the panel and the diagnostic
sensitivity of the testing used for each
gene vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this
GeneReview. Of note, given the rarity of some of the genes associated with hereditary pancreatitis, some panels may not include these genes. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused
exome analysis that includes genes specified by the clinician. (4) Methods used in a panel may include
sequence analysis,
deletion/duplication analysis, and/or other non-sequencing-based tests.
For an introduction to multigene panels click
here. More detailed information for clinicians ordering genetic tests can be found
here.
Comprehensive
genomic testing (which does not require the clinician to determine which
gene[s] are likely involved) may be considered.
Exome sequencing is most commonly used;
genome sequencing is also possible.
For an introduction to comprehensive
genomic testing click
here. More detailed information for clinicians ordering genomic testing can be found
here.
Note: Very few individuals with pancreatitis are found to have hereditary pancreatitis caused by a highly penetrant autosomal dominant pathogenic variant (e.g., PRSS1 p.Arg122His). Individuals with variant(s) in SPINK1,
CFTR, or CTRC associated with an increased risk for pancreatitis may only develop the disease in the presence of additional risk factors (e.g., see Risk Factors and Etiologies of Recurrent Acute Pancreatitis / Chronic Pancreatitis).
4. Medical Management of Pancreatitis
Evaluations Following Initial Diagnosis
Imaging of the pancreas is one of the most useful tests for staging pancreatic disease (asymptomatic, acute pancreatitis / recurrent acute pancreatitis, [AP/RAP], early chronic pancreatitis [CP], established CP, end-stage CP) and detecting some complications [Frøkjær et al 2018].
The initial test should be a CT scan to evaluate the size, shape and features of the pancreas including calcification, atrophy, pseudocysts, cysts, inflammatory masses, tumors, and extrapancreatic diagnoses.
MRI and MR cholangiopancreatography (MRCP) provide additional information about the parenchyma. Secretin-stimulated MRCP is more accurate than standard MRCP in the depiction of subtle ductal changes and for diagnosing pancreatic divisum. MRI is not as useful as CT for diagnosing pancreatic calcifications.
Endoscopic ultrasound (EUS) can also be used to diagnose parenchymal and ductal changes mainly during the early stage of the disease. The advantages of EUS include being able to add fine needle aspiration of suspicious lesions and diagnosis of microlithiasis in the biliary tree. However, early EUS changes are nonspecific and cannot be used to diagnose early CP.
Identifying changes in pancreatic function is often more challenging than imaging studies. The following evaluations are recommended:
Referral to a gastroenterologist specializing in the pancreas for evaluation of pancreatic exocrine function using invasive or noninvasive testing
Clinical measures of pancreatic exocrine insufficiency include observation of steatorrhea (fat and oil in the stool), symptoms of maldigestion (bloating, gas, cramps, and diarrhea), and nutritional deficiencies (e.g., fat-soluble vitamin deficiency and protein malnutrition with low albumin, prealbumin, or retinal binding protein).
Fecal elastase-1 analysis. Can be falsely positive with diarrhea, but can be used while an individual is taking pancreatic enzyme replacement therapy. The test is insensitive for mild pancreatic exocrine insufficiency.
Secretin-stimulated pancreatic bicarbonate secretion testing. Requires intubation of the duodenum and careful measurement of pancreatic bicarbonate secretion over about an hour (depending on the method). It is considered very sensitive, but primarily assesses pancreatic duct function. The test is intended to document a loss of pancreatic parenchyma but should be interpreted in the context of the
CFTR genotype since bicarbonate secretion is CFTR-dependent.
Serum trypsin or trypsinogen. A blood test that measures the leakage of pancreatic digestive enzymes (zymogens) into the blood stream. Under normal conditions a reduction in serum trypsin or trypsinogen levels reflects loss of parenchyma, with large reductions associated with exocrine pancreatic insufficiency. In some instances, abdominal pain is caused by mild acute pancreatitis flare and all pancreatic enzymes will be elevated in the blood, including trypsin and trypsinogen, possibly resulting in a pseudo-normalization of levels despite pancreatic insufficiency.
Referral to an endocrinologist for evaluation of pancreatic endocrine function (i.e., assessment of glucose tolerance) and lipid disorders (e.g., hypertriglyceridemia)
Annual fasting blood sugar, hemoglobin A1C, and fasting lipid panel are recommended. In addition, risk for type 2 diabetes should be noted including ancestry, family history, and body mass index [
Bellin et al 2017].
A standard glucose tolerance test or mixed meal test is recommended to evaluate beta-cell function and hormonal responses in individuals with pancreatitis. This can help sort out the cause of glucose intolerance including peripheral insulin resistance, beta-cell dysfunction, and/or islet cell loss.
Hypertriglyceridemia is a risk factor for RAP and CP. Endocrinologists typically measure fasting lipid levels as a risk for cardiovascular disease, whereas pancreatologists are more interested in peak levels as a risk for AP. There is no consensus on an approach. Endocrinologists, however, are the specialists who manage lipid disorders.
Referral to a pancreatic cancer surveillance program in persons with longstanding chronic pancreatitis. Risk for pancreatic cancer is highest in individuals with a history of smoking, a
familial cancer syndrome, a history of
Helicobacter pylori infections, non-type O blood group, and hereditary pancreatitis [
Maisonneuve & Lowenfels 2015].
Referral to a clinical geneticist and/or genetic counselor if the individual has a family history of pancreatitis or pancreatic cancer, or genetic testing identifies a high-risk
pathogenic variant
Treatment of Manifestations
Medical treatment and management for hereditary pancreatitis are similar to those for nonhereditary pancreatitis. AP is a sudden event that requires prompt evaluation by physicians trained in emergency medicine, gastroenterology, or abdominal surgery. Treatment of CP focuses on improving quality of life by managing pancreatic pain, maldigestion, and diabetes mellitus.
Pain can result from inflammation, ischemia, obstructed pancreatic ducts, pseudocysts, neuropathy, extrapancreatic locations from maldigestion, and central pain syndromes in some individuals.
Maldigestion can result from pancreatic exocrine insufficiency.
The amount of pancreatic enzyme replacement necessary depends on the diet and on the amount of residual pancreatic function (which diminishes over time). The normal amount of lipase secreted is about 750,000-1,000,000 units (USP) per meal. (Note that earlier papers used IU; 1 IU = 3 USP units [
Pongprasobchai & DiMagno 2005].) Since a minimum of 10% of normal pancreatic enzyme output is needed to digest a meal, about 70,000-80,000 USP units of lipase are required for an average-sized adult (70 kg) with total pancreatic insufficiency. The amount can be reduced for smaller persons and those with residual pancreatic exocrine function – while monitoring symptoms and nutritional parameters.
Pancreatic endocrine insufficiency results in diabetes mellitus.
Routine screening of individuals with chronic pancreatitis for glucose intolerance Recommendations for management and referral have been published [
Rickels et al 2013b].
Chronic pancreatitis with pancreatic exocrine insufficiency or pancreatic surgery may confound management of diabetes since the rate of nutrient digestion and absorption may be different from delivery of insulin (asynchrony). Attention to symptoms surrounding meals and multidisciplinary evaluation (gastroenterologists and endocrinologists) are needed to address these challenges. See also
Rickels et al [2013a] for consensus guidelines on management of diabetes in pancreatitis.
Prevention of Primary Manifestations
The ability to prevent the primary manifestations of pancreatitis is limited. The following recommendations are for individuals with (or at risk for) hereditary pancreatitis. Following these recommendations from early childhood may help prevent attacks of acute pancreatitis:
Low-fat diet. No formal guidelines for amount of dietary fat exist; however, some physicians recommend a low-fat diet to minimize pancreatic stimulation. If a low-fat diet is chosen, extra attention to providing fat-soluble vitamins (A, D, E, K) is needed. Some physicians recommend higher doses of PERT to compensate for altered pancreatic exocrine function.
Multiple small meals. No evidence-based guidelines exist; however, small meals may minimize pancreatic exocrine stimulation.
Good hydration. Maintaining good hydration may be helpful in minimizing attacks, especially since nausea, vomiting, and loss of appetite limit oral intake during an attack.
Cessation/abstinence from smoking and alcohol is the strongest recommendation for all persons with pancreatitis. Substantial evidence shows that oxidative stress from alcohol and tobacco smoke is inherently linked to progression and pain in pancreatitis [
Schoenberg et al 1995,
Petrov 2010,
Tandon & Garg 2011]. Smoking is also a major risk factor for pancreatic cancer [
Lowenfels et al 2001]. Note: Men with one high-risk
CLDN2 variant and women with two high-risk
CLDN2 variants should be strongly urged to stop drinking immediately and directed to effective treatment programs.
Exercise, yoga, and other relaxation techniques may increase quality of life in persons with pancreatitis [
Sareen et al 2007]. Some individuals report that regular exercise, such as running, helps reduce the frequency of episodes of pancreatitis [Authors, unpublished].
Agents/Circumstances to Avoid
Alcohol and tobacco. Smoking increases the risk for pancreatitis in a dose-dependent manner, doubling the risk for recurrent acute pancreatitis in heavy smokers (>35 pack years) [Maisonneuve et al 2005, Yadav et al 2009]. In combination, smoking and alcohol use increase the risk of developing pancreatitis eightfold [Yadav et al 2009]. Alcohol and tobacco exacerbate existing pancreatitis [Lowenfels & Whitcomb 1997]. Tobacco use also increases the risk of early onset of pancreatic cancer [Lowenfels et al 2001]. In individuals with hereditary pancreatitis, smoking doubles the risk for pancreatic cancer [Lowenfels et al 2001].
Dehydration worsens episodes of acute pancreatitis. Poor hydration (e.g., during exercise) can lead to episodes of pancreatitis [Authors, unpublished].
Physical and emotional stresses aggravate pancreatitis [Applebaum et al 2000]. Avoiding these stressors in families with hereditary pancreatitis may prevent or delay worsening of symptoms and progression of disease.
5. Genetic Risk Assessment
Genetic counseling is the process of providing individuals and families with
information on the nature, mode(s) of inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members; it is not meant to address all personal, cultural, or
ethical issues that may arise or to substitute for consultation with a genetics
professional. —ED.
Modes of Inheritance
Pancreatitis can occur as an isolated finding or as part of a rare genetic syndrome. This section reviews genetic counseling issues associated with isolated pancreatitis.
Pathogenic variants associated with an increased risk for pancreatitis as an isolated finding may be inherited in an autosomal dominant, autosomal recessive, or polygenic manner. The risk to family members depends on the underlying etiology.
Autosomal dominant hereditary pancreatitis (HP) is associated with either of the following:
Heterozygous
gain-of-function PRSS1 pathogenic variants (Generally, hereditary pancreatitis refers to
PRSS1-HP.)
Rare
heterozygous variants in
CTRC,
CPA1,
PRSS1, and
CEL that generate misfolding of the protein and an unfolded protein response
Autosomal recessive familial pancreatitis is associated with either of the following:
Polygenic inheritance is associated with either of the following:
The presence of
heterozygous pathogenic variants in two different pancreatitis-associated genes. Examples include:
CFTR +
SPINK1 and
CFTR +
CASR.
Additive or epistatic contributions of variants in multiple genes at different loci. Examples include
CFTR +
CTRC with a more severe course in the presence of a
PRSS1/2 risk
allele that increases trypsinogen expression or the
CLDN2 risk allele.
Autosomal Dominant Inheritance (PRSS1-HP) – Risk to Family Members
Parents of a proband
Sibs of a proband. The risk to the sibs of the proband depends on the genetic status of the proband's parents:
Offspring of a proband. Each child of an individual with PRSS1-related hereditary pancreatitis has a 50% chance of inheriting the pathogenic variant.
Other family members. The risk to other family members depends on the status of the proband's parents: if a parent is affected and/or known to be heterozygous for a pathogenic PRSS1 variant, the parent's family members may be at risk.
Autosomal Recessive Inheritance – Risk to Family Members
Parents of a proband
The risk for pancreatitis in individuals
heterozygous for a
pathogenic variant in a
gene associated with
autosomal recessive inheritance is presumed to be similar to that of the general population. Note: The risk for pancreatitis may be slightly increased if the heterozygous individual has additional genetic risk factors (i.e., a second heterozygous pathogenic variant in a different hereditary pancreatitis-associated gene or additive contributions of variants in multiple genes at different loci).
Sibs of a proband
If both parents are known to be
heterozygous for a
pathogenic variant, each sib of an affected individual has at conception a 25% chance of being affected, a 50% chance of being a
carrier, and a 25% chance of not being a carrier.
The risk for pancreatitis in individuals
heterozygous for a
pathogenic variant in a
gene associated with
autosomal recessive inheritance is presumed to be similar to that of the general population. Note: The risk for pancreatitis may be slightly increased if the heterozygous individual has additional genetic risk factors (i.e., a second heterozygous pathogenic variant in a different hereditary pancreatitis-associated gene or additive contributions of variants in multiple genes at different loci).
Offspring of a proband. The offspring of an individual with autosomal recessive hereditary pancreatitis are obligate heterozygotes for a pathogenic variant in a pancreatitis-related gene.
Other family members. Each sib of the proband's parents is at a 50% risk of being heterozygous for a pathogenic variant in a hereditary pancreatitis-related gene.
Heterozygote detection. Carrier testing for at-risk relatives requires prior identification of the pathogenic variants in the family.
Polygenic Inheritance – Risk to Family Members
Identification of heterozygous pathogenic variants in two different hereditary pancreatitis-associated genes or additive contributions of variants in multiple genes at different loci indicates complex disease and genetic risk assessment should be handled on a case-by-case basis. Specific combinations of genetic factors may be epistatic while others are additive. No systematic approach is available to predict the effects of most of these complex genotypes.
Prenatal Testing and Preimplantation Genetic Testing
Once the pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic testing for hereditary pancreatitis are possible.
Note: The reduced penetrance and inability to predict the natural disease course or severity of disease based on a genetic test result generally make interpretation of prenatal testing indeterminate.
Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing. While most centers would consider use of prenatal testing to be a personal decision, discussion of these issues may be helpful.
Chapter Notes
Author Notes
Dr Whitcomb is a physician-scientist who has dedicated his career to understanding the complexity of pancreatic physiology, pathophysiology, and pancreatic diseases in humans. He is the principal investigator of the Hereditary Pancreatitis Study and the North American Pancreatitis Study II (NAPS2), which includes over 25 major pancreas centers in the United States. He also serves as Chief, Division of Gastroenterology, Hepatology and Nutrition at the University of Pittsburgh and UPMC. He is the editor and webmaster of pancreas.org and co-editor, with Sheila Solomon, MS, CGC, of a patient-directed newsletter, Pancreas Education and Research Letter (PEaRL). Dr Whitcomb's work is focused on personalized medicine, with emphasis on early detection and prevention of a variety of pancreatic disorders using next-generation DNA sequencing, biomarkers, and comparative effectiveness research.
A specialized Pancreas Center of Excellence incorporating genetic testing and counseling early in the evaluation of pancreatic disease has been established [Whitcomb 2012].
Pancreas genetics research website. A summary of reported sequence variants in PRSS1, PRSS2, SPINK1, CTRC, and CPA1 is available at www.pancreasgenetics.org.
Author History
Jessica LaRusch, PhD (2014-present)
Celeste Shelton, PhD, CGC (2020-present)
Sheila Solomon, MS, CGC; GeneDx, Inc (2014-2020)
David C Whitcomb, MD, PhD (2014-present)
Revision History
2 July 2020 (sw) Comprehensive update posted live
13 March 2014 (me) Review posted live
20 December 2010 (dcw) Original submission